LOS ANGELES, CA / ACCESSWIRE / April 1, 2024 / Crown Electrokinetics Corp. (NASDAQ:CRKN) ("Crown" or the "Company"), ("Crown" or the "Company a leading smart glass technology company and an expert in constructing fiber optic networks, today announced its year-end 2023 financial results.
Financial Results for the year ended December 31, 2023 compared to 2022
Net Loss: Net loss for the year ended December 31, 2022, was $29.0 million This included $9.7 million of non-cash Other Expense primarily related to the balance sheet restructuring Crown executed in the first half of 2023. Net losses from operations were $19.3 million compared to 2022's $15.1 million net loss. This loss consisted of $5.8 million related to investment in the new Fiber Optics business and $13.5 million for the Film division, which also includes the corporate cost base.
Revenues: Total 2023 Revenues were $0.2 million which were all attributable to the Fiber division with the majority being booked in the 4th quarter.
Operating Expenses: Total Operating Expenses for the year-ended 2023 were $19.4 million with $0.9 million related to Fiber's cost of revenues, $1.6 million of depreciation, amortization and impairment, $2.2 million of Film R&D, which was $1.9 million lower than 2022, and $14.7 million of SG&A which is $4.1 million higher year on year - all due to investment in establishing the Fiber division.
Cash Position: For the year ended December 31, 2023, the Company deployed $16.7 million of cash for operations and $2.3 million for capital investment in the Fiber business. Crown raised $19.2 million from financing activities in 2023 with $14.8 million coming from common equity issuance via the ATM and Equity lines of credit, $3.1 million coming from Preferred stock and $1.3 million from debt notes. As of December 31, 2023, cash and cash equivalents were $1.1 million.
Updated Financial Guidance for First and Second Quarters of 2024
First Quarter 2024 Guidance - Revised
- Revenue for the first quarter of 2024 is now expected to be between $0.9 million and $1.0 million - compared to the previous guidance of $0.7 million and $0.9 million.
- Net Loss for the first quarter of 2024 is anticipated to be between ($3.1) million and ($3.3) million - compared to the previous guidance of ($3.3) million and ($3.5) million.
Second Quarter 2024 Guidance
- Revenue for the second quarter of 2024 is expected to be between $7.0 million and $ 8.0 million - no change.
- Net Income (Loss) for the second quarter of 2024 is anticipated to be between ($0.5) million and $0.0 million - no change.
The Company will host a conference call and audio webcast that morning at 11:00 a.m. Eastern time featuring remarks by Doug Croxall, Chairman & CEO and Joel Krutz, COO.
To participate in this event, please log-on or dial-in approximately 5 to 10 minutes before the beginning of the call.
Date: April 1, 2024
Time: 11:00 a.m. ETT
1-877-451-6152 or 1-201-389-0879
Conference ID: 13745352
Webcast:- https://viavid.webcasts.com/starthere.jsp?ei=1662854&tp_key=0ceef58cf5
Call me™: https://callme.viavid.com/viavid/?callme=true&passcode=13722237&h=true&info=company&r=true&B=6
Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link for instant telephone access to the event.
Call me™ link will be made active 15 minutes prior to scheduled start time.
Conference Call Replay Information
1-844-512-2921 or 1-412-317-6671
Access ID: 13745352
About Crown Electrokinetics
Crown is comprised of two divisions, Fiber Optics and Electrokinetics Film. The Electrokinetics Film division is a smart glass technology and the creator of our Smart Window Insert based on its patented electrokinetic film. Crown's Fiber Optics division is a builder of underground fiber optic networks as well as other utility infrastructure projects.
Safe Harbor Statement:
Statements in this news release may be "forward-looking statements". Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Crown Electrokinetic Corporation undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.
This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Crown Electrokinetics
IR Email: [email protected]
www.crownek.com
Crown Electrokinetics, Corp
Balance Sheets
(in thousands)
| December 31, 2023 | December 31, 2022 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash | $ | 1,059 | $ | 821 | ||||
Prepaid and other current assets | 728 | 590 | ||||||
Accounts receivable , net | 83 | - | ||||||
Total current assets | 1,870 | 1,411 | ||||||
Property and equipment, net | 3,129 | 1,409 | ||||||
Intangible assets, net | 1,382 | 1,598 | ||||||
Right of use asset | 1,701 | 1,842 | ||||||
Deferred debt issuance costs | 1,306 | 150 | ||||||
Other assets | 139 | 180 | ||||||
TOTAL ASSETS | $ | 9,527 | $ | 6,590 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 1,500 | $ | 865 | ||||
Accrued expenses | 1,190 | 621 | ||||||
Lease liability - current portion | 655 | 574 | ||||||
Warrant liability | - | 972 | ||||||
Notes payable at fair value | - | 1,654 | ||||||
Notes payable | 429 | 8 | ||||||
Warranty customer liability | 2 | - | ||||||
Total current liabilities | 3,776 | 4,694 | ||||||
Lease liability - non-current portion | 1,072 | 1,366 | ||||||
Warranty customer liability long term | 2 | - | ||||||
Total liabilities | 4,850 | 6,060 | ||||||
STOCKHOLDERS' EQUITY: | ||||||||
Preferred stock, par value $0.0001; 50,000,000 shares authorized, no shares outstanding | - | - | ||||||
Series A preferred stock, par value $0.0001; 300 shares authorized, 251 shares outstanding as of December 31, 2023 and December 31, 2022; liquidation preference $261 as of December 31, 2023 and zero as of December 31, 2022 | - | - | ||||||
Series B preferred stock, par value $0.0001; 1,500 shares authorized, 1,443 shares outstanding as of December 31, 2023 and December 31, 2022; liquidation preference $1,501 as of December 31, 2023 and zero as of December 31, 2022 | - | - | ||||||
Series C preferred stock, par value $0.0001; 600,000 shares authorized, 500,756 shares outstanding as of December 31, 2023 and December 31, 2022; liquidation preference $531 as of December 31, 2023 and zero as of December 31, 2022 | - | - | ||||||
Series D preferred stock, par value $0.0001; 7,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 1,058 as of December 31, 2022; liquidation preference zero as of December 31, 2023 and $1,113 as of December 31, 2022 | - | - | ||||||
Series E preferred stock, par value $0.0001; 77,000 shares authorized, 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022 | - | - | ||||||
Series F preferred stock, par value $0.0001; 9,073 shares authorized, 4,448 shares outstanding as of December 31, 2023 and no shares outstanding as of December 31, 2022; liquidation preference $4,753 as of December 31, 2023 and zero as of December 31, 2022 | - | - | ||||||
Series F-1 preferred stock, par value $0.0001; 9,052 shares authorized, 653 shares outstanding as of December 31, 2023 and no shares outstanding as of December 31, 2022; liquidation preference $696 as of December 31, 2023 and zero as of December 31, 2022 | - | - | ||||||
Series F-2 preferred stock, par value $0.0001; 9,052 shares authorized, 1,153 shares outstanding as of December 31, 2023 and no shares outstanding as of December 31, 2022; liquidation preference $1,371 as of December 31, 2023 and zero as of December 31, 2022 | - | |||||||
Common stock, par value $0.0001; 800,000,000 shares authorized; 25,744,157 and 338,033 shares outstanding as of December 31, 2023 and December 31, 2022, respectively | 7 | 2 | ||||||
Additional paid-in capital | 121,665 | 88,533 | ||||||
Accumulated deficit | (116,995 | ) | (88,005 | ) | ||||
Total stockholders' equity | 4,677 | 530 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 9,527 | $ | 6,590 | ||||
Crown Electrokinetics, Corp
Statements of Operations
(in thousands)
| Twelve months ended December 31, | ||||||||
| 2023 | 2022 | |||||||
Revenue | $ | 153 | $ | - | ||||
Cost of revenue, excluding depreciation and amortization | (886 | ) | - | |||||
Depreciation and amortization | (733 | ) | 503 | |||||
Research and development | (2,231 | ) | 4,107 | |||||
Selling, general and administrative | (14,962 | ) | 10,498 | |||||
Goodwill impairment charge | (649 | ) | - | |||||
Loss from operations | (19,308 | ) | (15,108 | ) | ||||
Other income (expense): | ||||||||
Interest expense | (9,417 | ) | (7 | ) | ||||
Loss on extinguishment of warrant liability | (504 | ) | 1,023 | |||||
Loss on extinguishment of debt | (2,345 | ) | ||||||
Gain on issuance of convertible notes | 64 | - | ||||||
Change in fair value of warrants | 10,458 | - | ||||||
Change in fair value of notes | (7,040 | ) | (149 | ) | ||||
Change in fair value of derivative liability | 401 | - | ||||||
Other expense | (1,293 | ) | (74 | ) | ||||
Total other income (expense) | (9,676 | ) | 793 | |||||
Loss before income taxes | (28,984 | ) | (14,315 | ) | ||||
Income tax expense | - | - | ||||||
Net loss | (28,984 | ) | (14,315 | ) | ||||
Statement of Cashflows
(in thousands)
| Year ended December 31, | ||||||||
| 2023 | 2022 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
Net loss | $ | (28,984 | ) | $ | (14,315 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Stock-based compensation | 714 | 2,405 | ||||||
Depreciation and amortization | 733 | 503 | ||||||
Loss on extinguishment of warrant liability | 504 | - | ||||||
Change in fair value of warrant liability | (10,458 | ) | (1,023 | ) | ||||
Change in fair value of liability | (401 | ) | - | |||||
Gain on issuance of convertible note | (64 | ) | - | |||||
Loss on extinguishment of debt | 2,345 | - | ||||||
Change in fair value of notes | 7,040 | 149 | ||||||
Amortization of deferred debt issuance costs | 9,341 | 73 | ||||||
Amortization of right of use assets | 626 | 494 | ||||||
Other expenses | 628 | - | ||||||
Impairment of Goodwill | 649 | - | ||||||
Intangible asset impairment | 200 | - | ||||||
| 214 | - | |||||||
Loss on disposal of equipment | 144 | 52 | ||||||
Changes in operating assets and liabilities: | ||||||||
Prepaid and other assets | 61 | 182 | ||||||
Accounts receivable | (83 | ) | - | |||||
Accounts payable | 1,253 | 413 | ||||||
Accrued expenses | 440 | 323 | ||||||
Lease liability | (1,062 | ) | (396 | ) | ||||
Net cash used in operating activities | (16,160 | ) | (11,140 | ) | ||||
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
Cash paid for acquisition of Amerigen 7 | (645 | ) | - | |||||
Purchase of equipment | (2,173 | ) | (751 | ) | ||||
Purchase of patents | - | (61 | ) | |||||
Net cash used in investing activities | (2,818 | ) | (812 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
Proceeds from the exercise of warrants | 2,062 | - | ||||||
Proceeds from the issuance of common stock and warrants, net of fees | - | 855 | ||||||
Proceeds from the issuance of common stock / At-the-market offering | 8,398 | 1,295 | ||||||
Proceeds from the issuance of notes in connection with Line of Credit | 2,350 | - | ||||||
Offering costs for the issuance of common stock / At-the-market offering | (170 | ) | (46 | ) | ||||
Proceeds from issuance of senior secured convertible notes and common stock warrants | - | 3,500 | ||||||
Proceeds from issuance of Series D preferred stock and warrants, net of fees | - | 1,039 | ||||||
Proceeds from issuance of Series F-1 preferred stock | 2,328 | - | ||||||
Proceeds from issuance of Series F-2 preferred stock | 748 | - | ||||||
Proceeds from issuance of January promissory notes, net of fees paid | 1,357 | - | ||||||
Repayment of notes payable | (2,348 | ) | - | |||||
Proceeds from the issuance of common stock in connection with equity line of credit, net of offering costs | 4,489 | - | ||||||
Net cash provided by financing activities | 19,214 | 6,643 | ||||||
Net increase / decrease in cash | 238 | (5,309 | ) | |||||
Cash - beginning of period | 821 | 6,130 | ||||||
Cash - end of period | 1,059 | $ | 821 | |||||
SOURCE: Crown Electrokinetics